Inmode Ltd

Inmode Ltd(INMD)股票分析

$13.370

-0.207 (-1.55%)收盘时

Loading chart…
最高
13.620
开盘
13.520
成交量加权均价
13.43
成交量
536.88K
市值
1.53B
最低
13.315
成交额
7.21M
企业价值/息税折旧摊销前利润(TTM)
7.91

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.

AI 分析 of Inmode Ltd (INMD)

持有

InMode Ltd is currently priced at $13.97, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 30.293, suggesting the stock is oversold, and the company has experienced a 10.73% decline over the past year. The main risk is the recent downgrade in analyst ratings and the uncertainty surrounding the acquisition bid, which could affect stock performance.

估值指标

Inmode Ltd(INMD)当前预期市盈率为 9.66,5 年平均预期市盈率为 12.15。

预期市盈率

合理
5 年均值 P/E
12.15
当前P/E
9.66
高估
18.24
低估
6.06

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
8.39
当前EV/EBITDA
7.91
高估
13.42
低估
3.35

预期市销率

合理
5 年均值 P/S
4.40
当前P/S
2.06
高估
6.98
低估
1.82

Alphio AI 对 INMD 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%INMD

$15.83

情景价格

基

基准

基准 · 50%INMD

$13.90

情景价格

悲

悲观

悲观 · 25%INMD

$12.59

情景价格

持有 INMD 的大户

H

Harel Insurance Investments & Financial Services Ltd

+ 持有INMD

+2.67%

3个月收益率

M

Meitav Investment House Ltd

+ 持有INMD

+1.07%

3个月收益率

事件时间线

2026-10-19 (ET)

08:30:00

Steel Partners Proposes to Acquire InMode at $16.75 per Share

2026-10-13 (ET)

07:30:00

InMode Finalizing Q3 2026 Financial Results

2026-10-12 (ET)

09:00:00

Applix Inc. Borrow Rate Increases to 12.22%

2026-08-05 (ET)

08:00:00

Sees FY26 Revenue of $365M-$375M

2026-07-10 (ET)

07:30:00

InMode Receives Acquisition Proposal from Steel Partners

资讯

INMD 常见问题 —— 由 Alphio AI 解答

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).

InMode Ltd is currently priced at $13.97, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 30.293, suggesting the stock is oversold, and the company has experienced a 10.73% decline over the past year. The main risk is the recent downgrade in analyst ratings and the uncertainty surrounding the acquisition bid, which could affect stock performance.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易